2 years ago

TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats

The stimulation of insulin secretion by glucose can be modulated by several nutritive, hormonal, and TAK-875 pharmacological inputs. Fatty aci read more...

2 years ago

TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats

Male ZDF (leprfa/CrlCrlj fatty fa/fa) rats and non-diabetic littermates, male Zucker lean (ZL leprfa/CrlCrlj lean +/+ or fa/+) rats, TAK-875 w read more...

2 years ago

TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats

Kind 2 diabetic issues mellitus is TAK-875 characterised by elevated plasma glucose stages arising from enhanced peripheral insulin resistance and the gr read more...

2 years ago

TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats

The system of the sturdy TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker read more...

2 years ago

TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats

TAK-875, a strong, selective and orally offered GPR40 agonist, read more...

2 years ago

TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats

To appraise in vivo effects read more...

2 years ago

TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats

The stimulation of insulin secretion by glucose can be modulated by a number of nutritive, hormonal, and TAK-875 pharmacological inputs. Fatty read more...